{"success":true,"data":{"pressRelease":{"id":"126349","rtpr_id":"nGNX5fkJ5b","ticker":"COSM","exchange":"NASDAQ","all_tickers":["COSM"],"title":"Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories","author":"Globe Newswire","published_at":"2026-08-24T19:40:00.100Z","article_body":"CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc.\n(https://www.globenewswire.com/Tracker?data=u1mXvNqNtlPw5DGA0puLbwIoJPpwrWjtVyc89PP8u76_aFpCqJOpI0Ny7ZDQrwubl0vjJk68_zObwrCKr_xz8sp7HFrPwfcGxY7eRykfA6Y=)\n(\"Cosmos Health\" or the “Company”) (NASDAQ:COSM)\n(https://www.globenewswire.com/Tracker?data=F4IxcCEQN5oClCeYV3Nu-kZ8Abcrcm4BXftC9gs9pF4FpvqkhHp8fYEKyE2Oj9CeONnZI7nPkdvyjSF-UYcJgQwExjJf0-SnsVLXJ1D1E04=),\na diversified, vertically integrated global healthcare group, today announced\nit is projecting Oliv18™ to generate over $6 million in incremental annual\nU.S. revenue within the next 12 to 18 months, representing approximately $4.3\nmillion in gross profit at an expected gross margin of approximately 72%.\n\nOliv18™ is part of the Company's \"18 Series,\" a growing portfolio of\nscience-based nutraceutical products. It is a whole olive polyphenol\nformulation, USDA and EU organic certified and produced through a 100%\nsolvent-free process, entering the U.S. market across the cardiovascular\nhealth and antioxidant categories.\n\nThe Company's projection is underpinned by a staged rollout beginning with\ndirect-to-consumer e-commerce, with planned expansion into selected retail\nchannels over time. The forecast incorporates internal assumptions around\npricing, anticipated sales volumes, repeat purchase behavior, and distribution\ngrowth, and remains subject to the continued execution of the Company's\ncommercialization plans.\n\nAccording to Grand View Research, the U.S. cardiovascular health supplements\nmarket was estimated at $2.11 billion in 2024 and is projected to reach $3.27\nbillion by 2030. The U.S. antioxidants market was valued at $1.66 billion in\n2025 and is projected to nearly double to $3.18 billion by 2035, according to\nPrecedence Research.\n\nGreg Siokas, CEO of Cosmos Health, stated: \"Oliv18™ extends our 18 Series\ninto two established categories in consumer wellness, where demand continues\nto shift toward products supported by scientific substantiation. We believe it\nhas the potential to become a meaningful revenue contributor to our\nnutraceutical portfolio as we scale distribution.”\n\nAbout Cosmos Health Inc.\nCosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at\nwww.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co,\nwww.cloudscreen.gr, as well as LinkedIn\n(https://www.globenewswire.com/Tracker?data=gWqmcRubDt7F7v6bZmr8-LZ5Eu2NUBfEDnTCrURHxdhKxCkjo5IFrDId0jziUYBPZr3d1VCwDixaUUBsWAF7AxBlEawZ6YN7g90jj7Bezr97yGUxY3KOZjV3KZOd86KD)\nand X\n(https://www.globenewswire.com/Tracker?data=s8vr0451p1eEj6tO-hMGtnQmr9cer1ExZIeMu68YsA8oxxAJsU7IDPHPeU0Jz8bNbNMDO78knsdpzukABTP52dgompJXBBiKydAdXt9dpFA=).\n\nForward-Looking Statements\nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas “believes,” “expects,” “anticipates,” “intends,”\n“projects,” “estimates,” “plans,” and similar expressions, or\nfuture or conditional verbs such as “will,” “should,” “would,”\n“may,” and “could,” generally identify forward-looking statements,\nalthough not all forward-looking statements contain these words. These\nstatements involve risks and uncertainties that may individually or materially\naffect the matters discussed herein for a variety of reasons outside the\nCompany’s control, including, but not limited to: the Company’s ability to\nraise sufficient financing to implement its business plan; the effectiveness\nof its digital asset strategies, including accumulation and yield-generating\nactivities; the impact of the war in Ukraine and ongoing conflicts in the\nMiddle East and other regions on the Company’s business, operations, and the\neconomy in general; the Company’s ability to successfully develop and\ncommercialize its proprietary products and technologies; changes in interest\nrates; changes in foreign currency exchange rates, commodity or other price\ninflation and deflation; our ability to issue debt on terms and at rates\nacceptable to us; the impact and expected outcome of investigations,\ninquiries, claims, and litigation; the challenges of operating in\ninternational markets; the adequacy of insurance coverage; the effect of\naccounting charges and of adopting certain accounting standards; the impact of\nlegal and regulatory changes, including changes to tax laws and regulations;\nguidance for fiscal 2026 and beyond and financial outlook. Forward-looking\nstatements are based on currently available information and our current\nassumptions, expectations and projections about future events. You should not\nrely on our forward-looking statements. These statements are not guarantees of\nfuture performance and are subject to future events, risks and uncertainties\n– many of which are beyond our control, dependent on the actions of third\nparties, or currently unknown to us – as well as potentially inaccurate\nassumptions that could cause actual results to differ materially from our\nhistorical experience and our expectations and projections. These risks and\nuncertainties include, but are not limited to, those described from time to\ntime in our periodic reports filed with the SEC and available at the SEC’s\nwebsite (www.sec.gov). There also may be other factors that we cannot\nanticipate or that are not described herein, generally because we do not\ncurrently perceive them to be material. Such factors could cause results to\ndiffer materially from our expectations. Forward-looking statements speak only\nas of the date they are made, and we do not undertake to update these\nstatements other than as required by law. You are advised, however, to review\nany further disclosures we make on related subjects in our filings with the\nSecurities and Exchange Commission and in our other public statements.\n\nInvestor Relations Contact:\nBDG Communications\ncosm@bdgcommunications.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5fkJ5b","title":"Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories","author":"Globe Newswire","ticker":"COSM","created":"2026-08-24T19:40:00.100Z","tickers":["COSM"],"exchange":"NASDAQ","article_body":"CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc.\n(https://www.globenewswire.com/Tracker?data=u1mXvNqNtlPw5DGA0puLbwIoJPpwrWjtVyc89PP8u76_aFpCqJOpI0Ny7ZDQrwubl0vjJk68_zObwrCKr_xz8sp7HFrPwfcGxY7eRykfA6Y=)\n(\"Cosmos Health\" or the “Company”) (NASDAQ:COSM)\n(https://www.globenewswire.com/Tracker?data=F4IxcCEQN5oClCeYV3Nu-kZ8Abcrcm4BXftC9gs9pF4FpvqkhHp8fYEKyE2Oj9CeONnZI7nPkdvyjSF-UYcJgQwExjJf0-SnsVLXJ1D1E04=),\na diversified, vertically integrated global healthcare group, today announced\nit is projecting Oliv18™ to generate over $6 million in incremental annual\nU.S. revenue within the next 12 to 18 months, representing approximately $4.3\nmillion in gross profit at an expected gross margin of approximately 72%.\n\nOliv18™ is part of the Company's \"18 Series,\" a growing portfolio of\nscience-based nutraceutical products. It is a whole olive polyphenol\nformulation, USDA and EU organic certified and produced through a 100%\nsolvent-free process, entering the U.S. market across the cardiovascular\nhealth and antioxidant categories.\n\nThe Company's projection is underpinned by a staged rollout beginning with\ndirect-to-consumer e-commerce, with planned expansion into selected retail\nchannels over time. The forecast incorporates internal assumptions around\npricing, anticipated sales volumes, repeat purchase behavior, and distribution\ngrowth, and remains subject to the continued execution of the Company's\ncommercialization plans.\n\nAccording to Grand View Research, the U.S. cardiovascular health supplements\nmarket was estimated at $2.11 billion in 2024 and is projected to reach $3.27\nbillion by 2030. The U.S. antioxidants market was valued at $1.66 billion in\n2025 and is projected to nearly double to $3.18 billion by 2035, according to\nPrecedence Research.\n\nGreg Siokas, CEO of Cosmos Health, stated: \"Oliv18™ extends our 18 Series\ninto two established categories in consumer wellness, where demand continues\nto shift toward products supported by scientific substantiation. We believe it\nhas the potential to become a meaningful revenue contributor to our\nnutraceutical portfolio as we scale distribution.”\n\nAbout Cosmos Health Inc.\nCosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at\nwww.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co,\nwww.cloudscreen.gr, as well as LinkedIn\n(https://www.globenewswire.com/Tracker?data=gWqmcRubDt7F7v6bZmr8-LZ5Eu2NUBfEDnTCrURHxdhKxCkjo5IFrDId0jziUYBPZr3d1VCwDixaUUBsWAF7AxBlEawZ6YN7g90jj7Bezr97yGUxY3KOZjV3KZOd86KD)\nand X\n(https://www.globenewswire.com/Tracker?data=s8vr0451p1eEj6tO-hMGtnQmr9cer1ExZIeMu68YsA8oxxAJsU7IDPHPeU0Jz8bNbNMDO78knsdpzukABTP52dgompJXBBiKydAdXt9dpFA=).\n\nForward-Looking Statements\nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas “believes,” “expects,” “anticipates,” “intends,”\n“projects,” “estimates,” “plans,” and similar expressions, or\nfuture or conditional verbs such as “will,” “should,” “would,”\n“may,” and “could,” generally identify forward-looking statements,\nalthough not all forward-looking statements contain these words. These\nstatements involve risks and uncertainties that may individually or materially\naffect the matters discussed herein for a variety of reasons outside the\nCompany’s control, including, but not limited to: the Company’s ability to\nraise sufficient financing to implement its business plan; the effectiveness\nof its digital asset strategies, including accumulation and yield-generating\nactivities; the impact of the war in Ukraine and ongoing conflicts in the\nMiddle East and other regions on the Company’s business, operations, and the\neconomy in general; the Company’s ability to successfully develop and\ncommercialize its proprietary products and technologies; changes in interest\nrates; changes in foreign currency exchange rates, commodity or other price\ninflation and deflation; our ability to issue debt on terms and at rates\nacceptable to us; the impact and expected outcome of investigations,\ninquiries, claims, and litigation; the challenges of operating in\ninternational markets; the adequacy of insurance coverage; the effect of\naccounting charges and of adopting certain accounting standards; the impact of\nlegal and regulatory changes, including changes to tax laws and regulations;\nguidance for fiscal 2026 and beyond and financial outlook. Forward-looking\nstatements are based on currently available information and our current\nassumptions, expectations and projections about future events. You should not\nrely on our forward-looking statements. These statements are not guarantees of\nfuture performance and are subject to future events, risks and uncertainties\n– many of which are beyond our control, dependent on the actions of third\nparties, or currently unknown to us – as well as potentially inaccurate\nassumptions that could cause actual results to differ materially from our\nhistorical experience and our expectations and projections. These risks and\nuncertainties include, but are not limited to, those described from time to\ntime in our periodic reports filed with the SEC and available at the SEC’s\nwebsite (www.sec.gov). There also may be other factors that we cannot\nanticipate or that are not described herein, generally because we do not\ncurrently perceive them to be material. Such factors could cause results to\ndiffer materially from our expectations. Forward-looking statements speak only\nas of the date they are made, and we do not undertake to update these\nstatements other than as required by law. You are advised, however, to review\nany further disclosures we make on related subjects in our filings with the\nSecurities and Exchange Commission and in our other public statements.\n\nInvestor Relations Contact:\nBDG Communications\ncosm@bdgcommunications.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-24T19:40:00.135369879Z","server_sent_at_ms":1787600400135},"received_at":"2026-08-24T19:40:00.187Z","source_url":"https://www.globenewswire.com/news-release/2026/08/24/3350084/0/en/cosmos-health-projects-over-6m-in-annual-revenue-and-4-3m-in-gross-profit-from-oliv18-across-the-u-s-cardiovascular-health-and-antioxidant-categories.html"},"analysis":{"id":"115291","press_release_id":"126349","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Revenue figures are projections based on internal assumptions, not historical results"],"eventType":"guidance_update","narrative":"Cosmos Health projects its new Oliv18™ product will generate over $6 million in annual revenue and $4.3 million in gross profit within the next 12 to 18 months.\n\nThe product, part of the company's '18 Series,' targets the U.S. cardiovascular health and antioxidant markets with an organic, solvent-free formulation.\n\nThe rollout begins with direct-to-consumer e-commerce before expanding into retail, supported by projected market growth in these categories.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Cosmos Health sets $6M revenue target for new nutraceutical Oliv18."},"keyFigures":{"guidance":"Over $6M in incremental annual U.S. revenue and $4.3M in gross profit within 12-18 months","customDimensions":{"projected_gross_profit_usd":4300000,"projected_annual_revenue_usd":6000000,"expected_gross_margin_percent":72}},"quotedText":"Oliv18™ extends our 18 Series into two established categories in consumer wellness, where demand continues to shift toward products supported by scientific substantiation.","namedEntities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["Oliv18™","18 Series"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM"},{"name":"Grand View Research","relationship":"market research firm"},{"name":"Precedence Research","relationship":"market research firm"}],"dollarAmounts":[{"amount":"over $6 million","context":"projected annual U.S. revenue from Oliv18™"},{"amount":"$4.3 million","context":"projected gross profit from Oliv18™"},{"amount":"$2.11 billion","context":"2024 U.S. cardiovascular health supplements market size (Grand View Research)"},{"amount":"$3.27 billion","context":"projected 2030 U.S. cardiovascular health supplements market size"},{"amount":"$1.66 billion","context":"2025 U.S. antioxidants market value"},{"amount":"$3.18 billion","context":"projected 2035 U.S. antioxidants market value"}]},"materialImpact":{"score":2,"reasoning":"The release provides specific forward-looking revenue projections for a new product. While the figures represent a potential meaningful contribution for a small-cap, they remain non-binding estimates subject to execution risk rather than realized material events."},"tickerRelevance":{"others":[],"primary":"COSM"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":["product_launch"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"product_projection","forwardLooking":true}},"event_type":"guidance_update","event_type_secondary":["product_launch"],"sentiment":"bullish","material_impact_score":2,"narrative":"Cosmos Health projects its new Oliv18™ product will generate over $6 million in annual revenue and $4.3 million in gross profit within the next 12 to 18 months.\n\nThe product, part of the company's '18 Series,' targets the U.S. cardiovascular health and antioxidant markets with an organic, solvent-free formulation.\n\nThe rollout begins with direct-to-consumer e-commerce before expanding into retail, supported by projected market growth in these categories.","key_figures":{"guidance":"Over $6M in incremental annual U.S. revenue and $4.3M in gross profit within 12-18 months","customDimensions":{"projected_gross_profit_usd":4300000,"projected_annual_revenue_usd":6000000,"expected_gross_margin_percent":72}},"named_entities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["Oliv18™","18 Series"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM"},{"name":"Grand View Research","relationship":"market research firm"},{"name":"Precedence Research","relationship":"market research firm"}],"dollarAmounts":[{"amount":"over $6 million","context":"projected annual U.S. revenue from Oliv18™"},{"amount":"$4.3 million","context":"projected gross profit from Oliv18™"},{"amount":"$2.11 billion","context":"2024 U.S. cardiovascular health supplements market size (Grand View Research)"},{"amount":"$3.27 billion","context":"projected 2030 U.S. cardiovascular health supplements market size"},{"amount":"$1.66 billion","context":"2025 U.S. antioxidants market value"},{"amount":"$3.18 billion","context":"projected 2035 U.S. antioxidants market value"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-24T19:41:11.315Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"product_projection","forwardLooking":true}},"durationMs":71121,"modelName":"glm-4.7"}}